Canaccord Genuity Group Forecasts Strong Price Appreciation for Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group (NASDAQ:PRVA) had its price objective upped by equities research analysts at Canaccord Genuity Group from $29.00 to $30.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target points to a potential upside of 20.14% from the stock’s current price.

PRVA has been the subject of several other reports. JPMorgan Chase & Co. raised their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, November 29th. Macquarie started coverage on Privia Health Group in a research note on Monday, December 16th. They issued an “outperform” rating and a $25.00 price target for the company. Truist Financial increased their price objective on Privia Health Group from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Needham & Company LLC boosted their target price on shares of Privia Health Group from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Friday. Finally, Stephens reaffirmed an “overweight” rating and set a $26.00 price target on shares of Privia Health Group in a research report on Thursday, January 2nd. One research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Privia Health Group has a consensus rating of “Buy” and a consensus price target of $26.47.

Privia Health Group Price Performance

NASDAQ:PRVA opened at $24.97 on Friday. The company has a market cap of $3.00 billion, a P/E ratio of 249.72, a P/E/G ratio of 3.47 and a beta of 0.87. The firm’s fifty day moving average price is $22.40 and its two-hundred day moving average price is $20.60. Privia Health Group has a one year low of $15.92 and a one year high of $26.04.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC grew its holdings in shares of Privia Health Group by 1.5% during the 3rd quarter. FMR LLC now owns 18,169,043 shares of the company’s stock valued at $330,858,000 after purchasing an additional 271,645 shares during the last quarter. Durable Capital Partners LP boosted its position in Privia Health Group by 3.4% in the fourth quarter. Durable Capital Partners LP now owns 11,487,843 shares of the company’s stock valued at $224,587,000 after buying an additional 378,255 shares in the last quarter. Riverbridge Partners LLC grew its stake in shares of Privia Health Group by 19.7% during the fourth quarter. Riverbridge Partners LLC now owns 5,824,458 shares of the company’s stock worth $113,868,000 after buying an additional 958,418 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Privia Health Group by 1.0% during the third quarter. Geode Capital Management LLC now owns 2,415,022 shares of the company’s stock worth $43,986,000 after buying an additional 23,178 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its stake in shares of Privia Health Group by 19.8% in the 4th quarter. Nuveen Asset Management LLC now owns 1,488,979 shares of the company’s stock valued at $29,110,000 after acquiring an additional 246,393 shares during the last quarter. Institutional investors own 94.48% of the company’s stock.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.